Business
Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials
Prescription product net revenue of $2.9 million in Q2 2022 increased approximately 12.0% Quarter over Quarter, over Q1 2022; and increased approximately 641%
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Prescription product net revenue of $2.9 million in Q2 2022 increased approximately 12.0% Quarter over Quarter, over Q1 2022; and increased approximately 641% Year over Year, over Mytesi® net revenue in Q2 2021Core initiatives:OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) adding international sites, targeting completion of enrollment 1H 2023Expected presentation in December 2022 of results of a third-party, investigator-initiated proof-of-concept trial of crofelemer for short bowel syndrome (SBS), supporting the potential for expanded patient access through programs in Europe in 2023Ongoing launch of Canalevia®-CA1 for treatment of chemotherapy-induced diarrhea (CID) in dogsREMINDER: Jaguar to host investor webcast Monday, August 22nd at 8:30 a.m. Eastern regarding second quarter 2022 financials and company updates; Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / August 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today provided Company updates and reported consolidated second-quarter 2022 financial results.Prescription product net revenue was approximately $2.9 million in the second quarter of 2022, representing an increase of approximately 12% over Mytesi net revenue in the first quarter of 2022, which totaled approximately $2.6 million, and an increase of approximately 641% over Mytesi net revenue in the second quarter of 2021, which totaled approximately $0.4 million.\"We are very pleased that growth in Mytesi (crofelemer) revenue continued in the second quarter of 2022,\" said Lisa Conte, Jaguar's president and CEO. \"We completed the full shift this past January to a patient access strategy that involves transitioning to a limited distribution network of specialty pharmacies, which reduced our distribution costs and improved our Mytesi gross-to-net ratio dramatically. It is wonderful to see Mytesi growth continuing following this transition and the other components of our Mytesi patient access program, including our ongoing educational and promotional activities in 2022 and the launch this past May of our telehealth initiative for Mytesi. Most importantly, we are pleased with the realization of our mission of providing relief with a novel, plant-based, first-in-class mechanism of action to patients in need - includin...